Klaroxin

Clarithromycin, the active ingredient in Klaroxin, is a macrolide antibiotic presented as an oral tablet for oral use. It treats bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis, chronic bronchitis exacerbations, skin and soft‑tissue infections, and is part of Helicobacter pylori eradication regimens.

GNH USA supplies Klaroxin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with consistent quality and regulatory compliance. The company adheres to EU Good Manufacturing Practices and provides reliable logistics for global distribution.

Clarithromycin is used to treat bacterial infections in several organ systems and disease categories. - Community‑acquired pneumonia: eradicates the causative bacteria, improving respiratory function and reducing disease severity. - Acute bacterial sinusitis: clears sinus infection, relieving congestion, facial pain and discharge. - Acute exacerbations of chronic bronchitis: reduces bacterial load, helping to restore airway patency and decrease cough. - Skin and soft‑tissue infections: eliminates pathogenic bacteria, promoting healing of cellulitis, abscesses and wound infections. - Helicobacter pylori eradication (in combination therapy): contributes to bacterial clearance as part of a multi‑drug regimen to treat peptic ulcer disease.

Clarithromycin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild stomach upset that may resolve with continued therapy. - Diarrhea: loose stools, occasionally leading to dehydration. - Abdominal pain: cramping or discomfort in the stomach area. - Taste disturbance: altered or metallic taste perception. - Headache: mild to moderate head pain. - Vomiting: occasional episodes of stomach emptying.

Serious or Rare Side Effects: - QT interval prolongation: may predispose to cardiac arrhythmias. - Severe allergic reactions: including anaphylaxis, rash, or angioedema. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Clostridioides difficile infection: severe colitis due to gut flora disruption. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: rare but life‑threatening skin reactions.

Before prescribing clarithromycin, clinicians should evaluate several safety considerations. - Assess liver function: monitor hepatic enzymes in patients with pre‑existing liver disease. - Monitor cardiac QT interval: avoid in patients with known QT prolongation or electrolyte disturbances. - Evaluate drug interactions: review concomitant medications that affect CYP3A4 metabolism. - Use with caution in renal impairment: dose adjustment may be required in severe renal dysfunction. - Avoid in known hypersensitivity: discontinue if allergic reactions occur. - Store at room temperature: keep in the original packaging, protect from moisture and heat.

Clarithromycin interacts with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase clarithromycin levels and toxicity. - Drugs that prolong QT interval (e.g., cisapride, pimozide): combined use can raise risk of serious arrhythmias. - Simvastatin and other high‑dose statins: risk of rhabdomyolysis due to increased statin concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Carbamazepine: may reduce clarithromycin efficacy and alter carbamazepine levels. - Oral contraceptives: may decrease hormonal effectiveness, advise additional contraception. - Digoxin: clarithromycin can raise digoxin levels, monitor serum concentrations. - Theophylline: may increase theophylline toxicity, observe for side effects.